ArticleMechanobiology in medicine2026
Mechanosensitive reactive oxygen Species:A precision medicine target for oxidative stress-related diseases.
Article in Mechanobiology in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress induced by abnormal mechanical stress is a common pathological mechanism underlying the initiation and progression of various injury and diseases. Mechanosensitive reactive oxygen species (mechano-ROS), a subset of ROS specifically elicited by mechanical stress, are primarily generated from distinct sources including NADPH oxidases (NOXs), mitochondrial electron transport chain (ETC), uncoupled endothelial nitric oxide synthase (eNOS), and xanthine oxidase (XO/XOR) in a disease-specific manner. These mechano-ROS act as critical signaling mediators that link aberrant mechanical cues to cellular dysfunction, inflammation, barrier disruption, and disease progression. Scavenging excessive reactive oxygen species (ROS) has thus emerged as a key strategy for mitigating injury and disease progression. However, the primary enzymatic systems and cellular sources responsible for ROS generation differ across diseases, which may partly account for the limited clinical efficacy of broad-spectrum antioxidant therapies. Consequently, targeted interventions that identify and inhibit disease-specific major ROS sources, in combination with ROS-scavenging strategies, could synergistically reduce oxidative stress by both upstream source suppression and downstream ROS clearance. This approach offers promising avenues for the precision attenuation/treatment of different injury and diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.